Fatigue in cancer patients receiving chemotherapy: an analysis of published studies

被引:84
作者
Iop, A [1 ]
Manfredi, AA [1 ]
Bonura, S [1 ]
机构
[1] Gen Hosp, Oncol Unit, I-33053 Udine, Italy
关键词
chemotherapy; fatigue; toxicity;
D O I
10.1093/annonc/mdh102
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Fatigue is a subjective experience that affects everybody. In healthy individuals, it can be considered a physiological response to physical or psychological stress. In people with specific diseases, however, fatigue often represents one of the most significant problems. Fatigue can be caused by many factors, both intrinsic to the patient and extrinsic, such as therapeutic interventions. This review, based on published studies, has been conducted with the aim of presenting a critical discussion of the available information on the characteristics, causes and potential treatments of fatigue in cancer patients receiving chemotherapy. The incidence of fatigue in these patients, the methods for measuring and evaluating fatigue, and possible therapeutic options are discussed. An appraisal of the toxicity of various chemotherapeutic agents is also presented. Although fatigue is now an ever,more considered aspect of the toxicity of chemotherapy, it remains difficult to establish what standard should be used to make a quali-quantitative evaluation of this symptom. Furthermore, in the absence of a clear demonstration of the efficacy of some therapies, the management of cancer-related fatigue remains poorly defined (except for the treatment of anemia-related fatigue). New randomized clinical trials are necessary to indicate the best strategies for tackling this important problem.
引用
收藏
页码:712 / 720
页数:9
相关论文
共 75 条
[1]
Aistars J, 1987, Oncol Nurs Forum, V14, P25
[2]
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease [J].
Ardizzoni, A ;
Hansen, H ;
Dombernowsky, P ;
Gamucci, T ;
Kaplan, S ;
Postmus, P ;
Giaccone, G ;
Schaefer, B ;
Wanders, J ;
Verweij, J .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2090-2096
[3]
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [J].
Batist, G ;
Ramakrishnan, G ;
Rao, CS ;
Chandrasekharan, A ;
Gutheil, J ;
Guthrie, T ;
Shah, P ;
Khojasteh, A ;
Nair, MK ;
Hoelzer, K ;
Tkaczuk, K ;
Park, YC ;
Lee, LW .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1444-1454
[4]
Blesch K S, 1991, Oncol Nurs Forum, V18, P81
[5]
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer.: A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD) [J].
Cascinu, S ;
Graziano, F ;
Ferraù, F ;
Catalano, V ;
Massacesi, C ;
Santini, D ;
Silva, RR ;
Barni, S ;
Zaniboni, A ;
Battelli, N ;
Siena, S ;
Giordani, P ;
Mari, D ;
Baldelli, AM ;
Antognoli, S ;
Maisano, R ;
Priolo, D ;
Pessi, MA ;
Tonini, G ;
Rota, S ;
Labianca, R .
ANNALS OF ONCOLOGY, 2002, 13 (05) :716-720
[6]
First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin [J].
Cassidy, J ;
Twelves, C ;
Van Cutsem, E ;
Hoff, P ;
Bajetta, E ;
Boyer, M ;
Bugat, R ;
Burger, U ;
Garin, A ;
Graeven, U ;
McKendrick, J ;
Maroun, J ;
Marshall, J ;
Osterwalder, B ;
Pérez-Manga, G ;
Rosso, R ;
Rougier, P ;
Schilsky, RL .
ANNALS OF ONCOLOGY, 2002, 13 (04) :566-575
[7]
Cella D, 1997, SEMIN HEMATOL, V34, P13
[8]
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer [J].
Chan, S ;
Friedrichs, K ;
Noel, D ;
Pintér, T ;
Van Belle, S ;
Vorobiof, D ;
Duarte, R ;
Gil, MG ;
Bodrogi, I ;
Murray, E ;
Yelle, L ;
von Minckwitz, G ;
Korec, S ;
Simmonds, P ;
Buzzi, F ;
Mancha, RG ;
Richardson, G ;
Walpole, E ;
Ronzoni, M ;
Murawsky, M ;
Alakl, M ;
Riva, A ;
Crown, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2341-2354
[9]
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck [J].
Colevas, AD ;
Norris, CM ;
Tishler, RB ;
Fried, MP ;
Gomolin, HI ;
Amrein, P ;
Nixon, A ;
Lamb, C ;
Costello, R ;
Barton, J ;
Read, R ;
Adak, S ;
Posner, MR .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3503-3511
[10]
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study [J].
Creemers, GJ ;
Bolis, G ;
Gore, M ;
Scarfone, G ;
Lacave, AJ ;
Guastalla, JP ;
Despax, R ;
Favalli, G ;
Kreinberg, R ;
VanBelle, S ;
Hudson, I ;
Verweij, J ;
Huinink, WWT .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) :3056-3061